These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20585239)

  • 1. Trends in surgery for Crohn's disease in the era of infliximab.
    Jones DW; Finlayson SR
    Ann Surg; 2010 Aug; 252(2):307-12. PubMed ID: 20585239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?
    Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA
    Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery, Crohn's disease, and the biological era: has there been an impact?
    Slattery E; Keegan D; Hyland J; O'donoghue D; Mulcahy HE
    J Clin Gastroenterol; 2011 Sep; 45(8):691-3. PubMed ID: 21135702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL; García-Paredes J; Cruz Santamaria DM; Lana R; Ramírez Fernández E; Rodríguez Asteaga E; Díaz-Rubio M
    Rev Esp Enferm Dig; 2002 May; 94(5):269-79. PubMed ID: 12474335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
    Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T; Göke B; Sackmann M
    Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
    Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.